PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology

SIMPLE SUMMARY: Atherosclerosis is a critical cardiovascular disease associated with the use of immune checkpoint inhibitors (ICIs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key orchestrator of atherosclerotic process and it is also involved in cancer progression and immune-resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Quagliariello, Vincenzo, Bisceglia, Irma, Berretta, Massimiliano, Iovine, Martina, Canale, Maria Laura, Maurea, Carlo, Giordano, Vienna, Paccone, Andrea, Inno, Alessandro, Maurea, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000232/
https://www.ncbi.nlm.nih.gov/pubmed/36900189
http://dx.doi.org/10.3390/cancers15051397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000232/
https://www.ncbi.nlm.nih.gov/pubmed/36900189
http://dx.doi.org/10.3390/cancers15051397

Ejemplares similares